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INTRODUCTION [249/250] 
Major efforts are being invested in the development of disease-modifying therapies for 
neurodegenerative disorders such as Huntington’s disease (HD).1  Testing their efficacy 
in clinical trials is a long and expensive process, with low success rates compared with 
other branches of medicine.2 In HD, no phase III studies of putative disease-modifying 
treatments have been successful, despite many showing promise during early testing. 
A wealth of observational data suggests that biomarkers of disease progression may 
facilitate the evaluation of disease-modifying therapies.3-6 MRI-derived neuroimaging 
measures appear particularly powerful, with data suggesting that substantially fewer 
patients would be required to detect a reduction in rate of change in MRI biomarkers, 
compared with clinical measures.3-9 However, many biomarkers have only been 
evaluated over intervals ≥12 months.  
It may be advantageous for clinical trials to have efficacy readouts over short intervals 
such as six months, especially during the early phases, in order to provide confidence-
instilling data that the trial should progress to a larger scale. However, the use of short-
interval biomarkers in clinical trials is critically dependent on their validation in 
longitudinal observational studies over the same time frame. 
Our objectives were to evaluate candidate outcomes for HD trials over 6-, 9- and 15-
month intervals, across neuroimaging, clinical and cognitive domains. Based on our 
findings, we present guidelines on the selection of outcomes for rapid readouts in 
clinical trials. It is hoped these data will directly inform the design of HD trials, 
facilitating the evaluation of treatments designed to slow the course of this devastating 
disease. 
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METHODS 
Study Design 
This was a longitudinal, case-control observational study in early-stage HD. Assessments 
were performed at baseline, six and 15 months.  The study was approved by the local 
ethical committees.   
Participants 
Between March and October 2011 forty controls and 61 HD patients were enrolled into 
Work Package 2 of the PADDINGTON study11 at Leiden (Netherlands), London (UK), Paris 
(France) and Ulm (Germany). Patients were recruited from research centres. Controls 
were spouses, partners or gene-negative siblings in order to match patients to controls 
as closely as possible in terms of age, education level, background and home life. 
Patients were required to be stage I of the disease,10 defined by a Unified Huntington’s 
Disease Rating Scale (UHDRS)12 Total Functional Capacity (TFC) ≥ 11, indicating good 
capacity in functional realms. Inclusion criteria included participants being 18–65 years 
of age, free from major psychiatric and concomitant neurological disorders, not 
currently participating in a clinical trial and able to tolerate and safely undergo MRI. 
Written informed consent was obtained from each subject.  
Procedures 
Clinical features were assessed using the UHDRS version 99. This included the Total 
Motor Score (TMS) which measures a range of motor features characteristically 
impaired in HD including gait, tongue protrusion, ocular function and postural stability; 
and the TFC scale which measures five components of daily living, including the capacity 
to work, manage finances and carry out domestic chores. The clinical examination was 
performed by raters certified by the European Huntington’s Disease Network (EHDN) 
UHDRS-TMS online certification (www.euro-hd.net).   
Cognitive features were assessed using the core EHDN cognitive battery, which consists 
of standard pencil and paper clinical neuropsychological tasks. All raters were trained on 
the battery and all tests were scripted. Each task is described in the Supplemental 
Methods. 
MRI acquisition 
3T MRI (T1-, T2- and diffusion-weighted) were acquired based on protocols standardised 
for multi-site use.6,11,13 Scan acquisition protocols have been described previously.11 
Quality control was performed on all datasets in pseudo-real time and rescans were 
requested where necessary. Data were pseudoanonymised and archived on a secure 
webportal. To avoid potential bias all image analysis was performed blinded to 
groupings.   
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MRI: macrostructural (volumetric) analysis 
Pre-defined regions-of-interest (ROIs) for the volumetric analysis included the caudate, 
putamen, white-matter, grey-matter, whole-brain, lateral ventricles and corpus 
callosum. Cortical thinning was also examined over each lobe (parietal, occipital, 
temporal and frontal). 
The software package MIDAS14 was used to delineate the whole-brain, caudate, corpus 
callosum and ventricles at baseline.11 Change in whole-brain, caudate and ventricular 
volume over the scanning interval was estimated using the Boundary Shift Integral (BSI) 
technique,15 optimised for multi-site data,16 within MIDAS software. The BSI is a semi-
automated tool which measures volume change over time (atrophy) directly from 
within-subject registered scan pairs. Change in corpus callosum and putamen volume 
was estimated by delineating the structures at both time-points, either manually11 
(corpus callosum) or with BRAINS3 software6,17 (putamen) and subtracting the volumes 
at each time-point. Grey-matter and white-matter volume changes were computed 
using a fluid-registration approach.5,18,19  
Cortical thickness measures were computed using FreeSurfer software 
(http://surfer.nmr.mgh.harvard.edu/; version 5.3.0). All scans were run through the 
longitudinal pipeline20 and thickness estimates (mm) were extracted from each region 
defined by the Desikan-Killiany Atlas and averaged within lobes.21 
Full details of all volumetric image analysis are provided in the Supplemental Methods. 
MRI: microstructural (diffusion) analysis 
Diffusion metrics of fractional anisotropy (FA), mean diffusivity (MD), axial diffusivity 
(AD) and radial diffusivity (RD) were generated over pre-defined ROIs (white matter, 
corpus callosum, caudate and putamen) for all three visits using a longitudinal 
registration pipeline. In brief, a common ROI mask was defined in a temporally unbiased 
‘mid-space’ based on within-subject registration of T1 images, before being non-linearly 
registered to each individual’s native FA images for each visit. The mean values were 
then calculated across all included voxels for the four DTI metrics. This analysis is 
described in detail in the Supplemental Methods. 
All segmentations and registrations were visually inspected for accuracy by trained 
analysts, blinded to diagnosis. Excluded data-points are described in Supplemental End-
point Quality Control data. 
Statistical analysis 
Statistical analysis was performed by an independent team according to a predefined 
analysis plan. The repeated measures of each outcome variable were analysed using 
generalised least squares regression models, with variances of the outcome (and 
correlations between pairs of measures) allowed to differ both by group and by visit The 
models included a group factor (early HD or Control), calendar time from baseline (in days) and 
a quadratic term to allow non-linear change over the three visits to be modelled. The use of 
Hobbs et al. p6 
 
 
GLS models that jointly model all available outcomes provides some additional 
protection against the impact of missing values. Data only requires a “missing at 
random” assumption rather than the more restrictive “missing completely at random” 
assumption to give unbiased estimates. (REF) Where outcomes directly measured 
changes (such as whole-brain atrophy between two visits) the outcome variables in the 
statistical models were change between baseline and six months (i.e. 6-month interval), 
change between baseline and 15 months (i.e. 15-month interval) and change between 
six and 15 months (i.e. 9-month interval). Otherwise outcomes were measures made at 
baseline, six and 15 months. Linear and quadratic effects of time were included in all 
models with estimated between-group differences for the 6-, 9- and 15-month intervals 
calculated using appropriate linear combinations of model parameters. All analyses 
adjusted forbaseline age, gender and study site as well as interactions with the linear 
and quadratic effects of time. This was due to an a priori belief that age, gender and 
study site might affect slopes (and rates of change in slopes) as well as absolute levels of 
the outcomes. Models for non-imaging outcomes adjusted additionally for educational 
level (an ordered categorical variable treated as a continuous covariate) and its 
interactions with linear and quadratic effects of time because education level may affect 
performance on such outcomes, and education levels were expected to differ 
systematically between HD and controls.  
 
Longitudinal Effect Sizes (ES) with 95% confidence intervals (CIs) for the difference in 
change over each interval were calculated as the covariate-adjusted difference in the 
mean of the change between HD participants and controls, divided by the estimated 
residual standard deviation (SD) of change in HD participants. Expression of results as 
(unit-free) ES permits comparison of changes measured using different metrics. Such ES 
(when squared) are inversely related to sample-size requirements for clinical trials 
under the reasonable assumption that a 100% effective treatment will reduce the mean 
rate of change in HD cases to that in healthy controls without affecting the variability in 
these rates.10 95% CIs for the ES were calculated using bias corrected and accelerated 
(BCa) bootstrapping, with 2000 replications.22 Here an ES of two implies that the mean 
change in HD is two SD away from that in controls. No adjustment for multiple 
comparisons was made since there is independent scientific interest in each of the 
variables.23 Throughout, a cut-off of p=0.05 was used to establish formal statistical 
significance, with the actual p-values also considered in the interpretation of results. All 
analysis was performed in STATA v12. 
Hobbs et al. p7 
 
 
 
 
Figure 1 Relationship between effect sizes and sample-size requirements for 
randomised controlled trials where the outcome is a change measure between two 
time points.  Plots of this relationship are shown for treatments with efficacy levels of 25% (red), 50% 
(blue) and 100% (green), assuming 90% power and a 5% significance level. 
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RESULTS 
Participants 
At baseline, five HD participants were granted waivers for being outside disease-stage 1; 
four were stage 2, one was stage 3.11 All controls and 59/61 HD participants returned for 
the 6-month assessment; HD drop-out was due to illness (n=2), both returned for the 
15-month visit. 37/40 controls and 56/61 HD participants returned for the 15-month 
assessment; HD drop-out was due to disease-related burden (n=1), inability to tolerate 
scanning (n=1), treatment for cancer (n=1) and psychiatric burden resulting in the site 
investigator withdrawing the participant (n=2).  Drop out in the control group was due 
to being the spouse of a withdrawn HD participant (n=1) or personal issues unrelated to 
the study (n=2).  
Age and gender were well-balanced between groups (Table 1). Within the HD group, 
CAG, disease burden21 and TFC were well-balanced between sites (Supplemental Table 
1). The average intervals (in months) between assessments in the HD group were 5.76 
(1.36)) 9.12 (0.99) and 14.88 (1.33). In the control group the intervals were 5.48 (1.08), 
9.08 (0.88) and 14.50 (1.09) 
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Table 1. Participant demographics at baseline All study participants attended for at 
least 1 follow up clinical visit.  
Characteristic Controls  (N=40) HD Stage I  (N=61) 
Age (Years) 
51.42 (8.40) 
28.98 – 
66.64 
48.65 
(10.84) 
23.49 – 
67.29 Mean (SD)   Min – Max 
Gender 
    
Female N (%) 23 (57.50%) 37 (60.66%) 
Site 
    
Leiden N (%) 10 (25%) 17 (27.87%) 
London N (%) 10 (25%) 16 (26.23%) 
Paris N (%) 10 (25%) 13 (21.31%) 
Ulm N (%) 10 (25%) 15 (24.59%) 
Total Motor Score 
1.38 (1.85) 0-7 
20.07 
(10.73) 
6-58 
Mean (SD) Min-Max 
Total Functional Capacity 
12.98 (0.16) 12-13 11.74 (1.45) 5-13 
Mean (SD) Min-Max 
CAG 
  43.77 (3.20) 39 – 54 
Mean (SD)   Min – Max 
  
Disease Burden Score * 
  
376.46 
(85.15) 
226.41 – 
559.18 Mean (SD)   Min – Max 
  
Total Functional Capacity 
Breakdown by site     
N (%) 
    
TFC 11-13 (HD Stage 1) 
  
56 (91.80%) 
TFC 7-10 (HD Stage 2) 
  
4a (6.56%) 
TFC 3-6 (HD Stage 3) 
  
1b (1.64%) 
* Penny
24
 Disease Burden Formula: Age x (CAG - 35.5) 
a 
3 London, 1 Paris. 
b 
 Paris 
 
Effect sizes  
ES for the difference in 6-, 9- and 15-month change between HD participants and 
controls are presented in Table 2. Unadjusted baseline, 6- and 15-month findings for 
each outcome, with the number of data points for each variable, are presented by group 
in Supplemental Tables 3 and 4, with adjusted between-group differences in change 
over the 6-, 9-, and 15-month intervals. 
 
Hobbs et al. p10 
 
 
 
 Effect Size Estimate (95% CI) 
6-month interval 9-month interval  15-month interval 
Cognitive battery 
Letter Fluency  0.133 
(-0.4 , 0.603) 
0.618 
(-0.074 , 1.183) 
0.664 
(-0.031 , 1.32) 
Category Fluency  0.226 
(-0.212 , 0.663) 
0.125 
(-0.417 , 0.662) 
0.348 
(-0.204 , 0.892) 
HVLT delayed recall  0.491 
(-0.006 , 0.926) 
0.001 
(-0.525 , 0.531) 
0.502 
(-0.122 , 1.033) 
HVLT total correct  0.115 
(-0.357 , 0.589) 
0.119 
(-0.329 , 0.609) 
0.208 
(-0.181 , 0.584) 
HVLT Recognition  0.189 
(-0.147 , 0.449) 
-0.264 
(-0.692 , 0.075) 
-0.159 
(-0.837 , 0.32) 
Symbol Digit Modalities Test (SDMT) 0.637 
(0.08 , 1.154) 
0.343 
(-0.108 , 0.808) 
0.799 
(0.344 , 1.254) 
Trail A Time (seconds)  0.209 
(-0.103 , 0.471) 
-0.055 
(-0.369 , 0.31) 
0.212 
(-0.115 , 0.574) 
Trail B Time (seconds)  0.114 
(-0.265 , 0.443) 
-0.23 
(-0.678 , 0.164) 
-0.073 
(-0.492 , 0.25) 
Stroop Word  0.285 
(-0.086 , 0.573) 
0.063 
(-0.257 , 0.448) 
0.305 
(-0.081 , 0.614) 
Stroop Colour  0.25 
(-0.191 , 0.684) 
0.192 
(-0.227 , 0.594) 
0.36 
(-0.026 , 0.705) 
Stroop Interference  0.176 
(-0.194 , 0.539) 
0.303 
(-0.11 , 0.685) 
0.492 
(-0.026 , 0.943) 
UHDRS clinical scales 
TMS (square root)  0.047 
(-0.473 , 0.609) 
0.58 
(0.087 , 1.096) 
0.545 
(0.075 , 1.123) 
TFC score  0.337 
(-0.532 , 1.325) 
0.176 
(-1.05 , 1.323) 
0.388 
(-0.478 , 1.241) 
Microstructural (diffusion) neuroimaging metrics 
Caudate FA  0.37 
(-0.125 , 0.826) 
0.285 
(-0.109 , 0.651) 
0.518 
(0.12 , 0.878) 
Caudate MD (mm
2
/s)  0.539 
(0.199 , 0.83) 
0.62 
(0.173 , 1.029) 
1.111 
(0.77 , 1.434) 
Caudate RD (mm
2
/s) 0.522 
(0.178 , 0.815) 
0.611 
(0.178 , 1.017) 
1.067 
(0.729 , 1.387) 
Caudate AD (mm
2
/s) 0.562 
(0.211 , 0.859) 
0.627 
(0.145 , 1.059) 
1.174 
(0.839 , 1.493) 
Putamen FA  -0.036 
(-0.359 , 0.301) 
-0.206 
(-0.558 , 0.152) 
-0.269 
(-0.654 , 0.139) 
Putamen MD (mm
2
/s) 0.433 
(0.147 , 0.72) 
0.286 
(-0.074 , 0.636) 
0.723 
(0.384 , 1.017) 
Putamen RD (mm
2
/s) 0.328 
(0.06 , 0.603) 
0.217 
(-0.154 , 0.562) 
0.567 
(0.231 , 0.868) 
Putamen AD (mm
2
/s) 0.553 
(0.229 , 0.851) 
0.379 
(0.034 , 0.723) 
0.92 
(0.526 , 1.261) 
White Matter FA  0.234 -0.089 0.165 
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(-0.164 , 0.638) (-0.477 , 0.285) (-0.284 , 0.65) 
White Matter MD (mm
2
/s) 0.499 
(0.072 , 0.93) 
0.188 
(-0.148 , 0.536) 
0.615 
(0.197 , 1.095) 
White Matter RD (mm
2
/s) 0.39 
(-0.053 , 0.785) 
0.103 
(-0.21 , 0.419) 
0.506 
(0.08 , 0.944) 
White matter AD (mm
2
/s) 0.495 
(0.075 , 0.887) 
0.275 
(-0.074 , 0.813) 
0.614 
(0.212 , 1.139) 
Corpus Callosum FA  0.432 
(0.112 , 0.818) 
0.148 
(-0.206 , 0.471) 
0.681 
(0.17 , 1.147) 
Corpus Callosum MD (mm
2
/s) 0.249 
(-0.183 , 0.763) 
0.147 
(-0.304 , 0.562) 
0.304 
(-0.117 , 0.899) 
Corpus Callosum RD (mm
2
/s)   0.371 
(-0.004 , 0.876) 
0.102 
(-0.318 , 0.498) 
0.413 
(-0.048 , 1.034) 
Corpus Callosum AD (mm
2
/s) 0.015 
(-0.351 , 0.379) 
0.235 
(-0.235 , 0.641) 
0.211 
(-0.157 , 0.719) 
Macrostructural (volumetric) neuroimaging metrics 
Caudate atrophy, CBSI (% baseline)  0.697 
(0.359 , 1.021) 
0.638 
(0.324 , 0.981) 
1.191 
(0.742 , 1.687) 
Whole-brain atrophy, BBSI (% baseline)  0.479 
(0.157 , 0.774) 
0.698 
(0.314 , 1.064) 
0.865 
(0.465 , 1.199) 
Ventricular  expansion, VBSI (mls)  0.791 
(0.412 , 1.143) 
0.925 
(0.553 , 1.279) 
1.025 
(0.672 , 1.323) 
Grey matter atrophy (% baseline)  0.772 
(0.243 , 1.23) 
0.612 
(0.304 , 1.101) 
0.86 
(0.554 , 1.219) 
White matter atrophy (% baseline)  0.615 
(0.261 , 1.028) 
0.93 
(0.566 , 1.283) 
0.957 
(0.589 , 1.325) 
Putamen atrophy (% baseline)  0.101 
(-0.187 , 0.397) 
0.538 
(0.2 , 0.899) 
0.777 
(0.331 , 1.183) 
Corpus callosal atrophy (% baseline) 0.113 
(-0.272 , 0.557) 
0.170 
(-0.213 , 0.609) 
0.205 
(-0.191 , 0.63) 
Macrostructural (cortical thinning) neuroimaging metrics 
Frontal lobe cortical thinning (mm) -0.097 
(-0.519 , 0.292) 
-0.054 
(-0.513 , 0.42) 
-0.173 
(-0.76 , 0.406) 
Parietal lobe cortical thinning (mm) 0.043 
(-0.315 , 0.415) 
0.247 
(-0.153 , 0.647) 
0.376 
(-0.109 , 0.855) 
Temporal lobe cortical thinning (mm) 0.293 
(-0.154 , 0.752) 
0.058 
(-0.326 , 0.51) 
0.254 
(-0.122 , 0.695) 
Occipital lobe cortical thinning (mm) 0.295 
(-0.161 , 0.771) 
0.22 
(-0.196 , 0.667) 
0.512 
(0.011 , 0.997) 
Table 2. 6-, 9- and 15-month Effect Size Estimates. 
ES estimates and 95% bias corrected and accelerated CIs over 6-, 9- and 15-month intervals for 
differences between change in HD and control participants.All analyses adjusted for age, gender and 
study site as well as interactions with the linear and quadratic effects of time. Models for non-imaging 
outcomes adjusted additionally for educational level and its interactions with linear and quadratic effects 
of time. Expression of results as ES permits comparison of changes measured using different metrics. Such 
ES (when squared) are inversely related to sample-size requirements for clinical trials under the 
assumption that a 100% effective treatment will reduce the mean rate of change in HD to that in healthy 
controls, without affecting the variability.  
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For clinical applicability, Table 2 should be viewed in conjunction with Figure 1, which 
depicts the relationship between ES and sample-size requirements for disease-
modifying clinical trials (where the outcome is a single change measured between two 
time points) for varying assumed treatment efficacies. 
Macrostructural neuroimaging measures 
Longitudinal atrophy of the caudate, white-matter, grey-matter and whole-brain, and 
expansion of the lateral ventricles, produced relatively large ES over 6-, 9- and 15-month 
intervals (Table 2); with all between-group differences statistically significant (p<0.05, 
Supplemental Table 4). ES for these metrics were relatively consistent in that they 
tended to change in magnitude relative to the interval size. Caudate atrophy and 
ventricular expansion performed particularly strongly over the 6-month interval.   
Putamen atrophy ES were small and not statistically significant over the 6-month 
interval (ES 0.101; 95% CI -0.187, 0.397) but performed more strongly over 9- and 15-
months, although ES were smaller than for the caudate and the other more global 
atrophy metrics listed above (Table 2). Corpus callosal atrophy was not significantly 
higher than in controls over all time intervals examined (Supplemental Table 3). 
Cortical thinning ES were small and between-group differences were only statistically 
significant for the occipital cortex over the 15-month interval (p=0.032, Supplemental 
Table 3); however this ES was relatively small with a wide CI (0.512; 95% CI 0.011, 
0.997). 
Microstructural neuroimaging measures 
The microstructural (diffusion) metrics had typically smaller ES than the macrostructural 
atrophy measurements, although the caudate diffusivity metrics performed strongly 
(Table 2, Supplemental Table 3). In particular, caudate MD produced ES comparable to 
caudate atrophy over the 9- and 15-month intervals.  
FA ES were small and not statistically significant progression over all intervals and for all 
structures examined (caudate, putamen, global white-matter and corpus callosum). 
Clinical measures 
The standard clinical scales examined (TFC and TMS) performed relatively poorly. 
Between-group differences in TFC were not statistically significant over 6-, 9- or 15-
month intervals (Supplemental Table 3) and corresponding ES were small, with CIs 
spanning zero. TMS performed more strongly than TFC over the 9- and 15-month 
intervals, with significant between-group differences and larger ES, although the CIs 
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surrounding the ES estimates were wide (TMS over 15 months; ES 0.545 (95% CI: 0.075, 
1.123)). 
Cognitive measures 
Changes in the majority of tasks in the cognitive battery did not differ significantly 
between HD and controls over all intervals examined (Table 2, Supplemental Table 3). 
The Symbol Digit Modality Task (SDMT) was the most promising non-imaging measure 
over 15 months (ES 0.799; 95% CI: 0.344 to 1.254). However, this measure lacked 
consistency over the shorter intervals, with 6-month and 9-month ES of 0.637 (95% CI: 
0.08 to 1.154) and 0.348 (95% CI: -0.108, 0.808) respectively. 
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DISCUSSION 
Employing a multi-site study design with variable, short-interval observational periods, 
we report 6-, 9- and 15-month ES for a range of biomarker candidates of HD progression 
across multiple assessment modalities (macro- and micro-structural neuroimaging, 
clinical and cognitive). Reported ES can be used with a standard formula to calculate 
sample-size requirements for disease-modifying clinical trials10 (Figure 1). This is the first 
time that ES have been reported over the short intervals of six and nine months. It is 
hoped that these data will be used to directly inform clinical trial design. 
Key Results 
Longitudinal changes in macrostructural neuroimaging measures such as caudate 
atrophy and ventricular expansion in early HD subjects were larger than those in 
controls giving rise to consistently large ES over the 6-, 9- and 15-month intervals, in 
agreement with previous multi-site observational findings over periods of 12-months 
and longer (Tabrizi 2011, 2012, 2013 etc). Analogous ES for cortical metrics were smaller  
particularly over the shorter intervals, although occipital cortical thinning showed some 
promise over 15 months.  Microstructural (diffusion) neuroimaging metrics ES were also 
typically smaller over the shorter intervals, although caudate diffusivity metrics 
performed strongly over 9 and 15 months, in line with the most promising atrophy 
measures.  To our knowledge, this is the first longitudinal multi-site study to examine 
change in diffusion metrics in HD.  Findings are encouraging, particularly within the 
striatal grey matter, in accordance with a recent report over 18 months in a single-site 
study (Dominguez PLOS one 2013).   
Clinical and cognitive outcomes exhibited small longitudinal ESs, particularly over 6- and 
9-month intervals, with wide confidence intervals  indicating a lack of precision. Of note, 
SDMT appeared particularly promising over the 6-month interval, producing ES 
comparable with caudate atrophy, although with noticeably wider confidence intervals. 
However, this result was not replicated over the 9-month interval, suggesting it to be a 
chance finding.  Over 15 months, SDMT performed strongly, producing ES comparable 
with putamen atrophy.  These longer-interval findings are in line with previous reports 
over 12- and 24-months, showing SDMT to be one of the most promising cognitive 
outcomes (Tabrizi 2011, 2012. Paulsen. Stout JNNP 2012). 
Interpretation: Clinical application 
To interpret findings within the context of designing disease-modifying clinical trials in 
HD, we must consider that although certain neuroimaging measures appear to be 
particularly powerful, they would not be accepted as primary end-points in trials since 
they do not provide a direct measure of how the patient feels, functions or survives 
(www.fda.gov). Hence, to exploit the potential of these neuroimaging measures, we 
propose their use as: (1) initial short-term readouts in early phase/proof-of-concept 
(PoC) studies over six months; (2) interim or safety readouts over six or nine months in 
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longer, larger efficacy studies (e.g. Phase III), and as; (3) secondary end-points in efficacy 
studies over longer periods such as 15 months.  
Short-term readouts  
Macrostructural neuroimaging measures such as caudate atrophy and ventricular 
expansion may be able provide early confidence-instilling readouts in Phase II PoC 
studies over intervals such as 6 and 9 months months, where the goal would be to 
assure safety and gather initial evidence that the therapy had promising properties. 
Encouraging findings from such readouts would facilitate the decision whether to 
further invest in the therapy, increasing participant numbers and trial duration. An 
adaptive approach such as this based on early, meaningful data could improve the 
viability of disease-modifying clinical trials in HD.  
Interim read-outs and secondary end-points 
Once sufficiently powered, disease-modification could be demonstrated in large-scale 
Phase III efficacy studies of longer duration such as 15 months, using approved clinical 
measures such as TMS as the primary end-point, and specific neuroimaging metrics as 
secondary end-points. Supportive data from a strong neuroimaging biomarker 
programme would be important in demonstrating disease modification.  
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Figure 2 Suggested biomarker selection for trials of a 50% effective disease-modifying 
agent Sample-size requirements are per treatment arm; calculated using the standard formula10, with 
90% power and two-tailed p<0.05, for therapies with 50% estimated treatment efficacy. 
Recommendations are given as ticks ("show potential"), crosses ("unlikely to be suitable") and question 
marks (“further data required – wide confidence intervals”). 
Figure 2 provides an example of how the ES data presented in Table 2 could be used to 
inform clinical trial design.  Sample-size requirements are presented for the most 
promising outcomes from each assessment modality (Table 2), based on a treatment 
hypothesised to reduce the rate of change in each outcome by 50% (90% power and 5% 
significance level).  Based on these results, recommendations for selecting biomarkers 
for short PoC studies and longer-term Phase III trials are provided as “ticks” (show 
potential), “crosses” (unlikely to be suitable) and “question marks” (further data is 
required due to wide confidence intervals).  An important caveat of this figure is that 
sample sizes are heavily dependent on the magnitude of the hypothesised treatment 
effect (Figure 1).  For example, requirements would be 4x larger if the effect was 
reduced to 25%.  Nevertheless, this approach does provide an estimate of sample-size 
requirements to sufficiently power trials, as well as a means of comparing the outcomes 
across assessment modalities. 
For example, in order to detect therapeutic effects on ventricular expansion following 
treatment periods of 6-, 9- or 15-months, sample-size requirements per treatment arm 
would be 134 (95% CI: 64, 495), 98 (95% CI: 51, 275) and 80 (95% CI: 48, 186) 
respectively, for 50% efficacy.  Considering the magnitude of the sample sizes and the 
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width of the confidence intervals, ventricular expansion may be a suitable biomarker for 
use in short-term PoC studies, as well as trials over a longer duration (Figure 2).   
Conversely, to assess the effect of a therapy on motor progression, the commonly-
applied UHDRS-TMS may be suitable for use over 9- and 15-month intervals, given a 
50% treatment effect; however, the wide confidence intervals around these sample 
sizes indicate a lack of precision (Figure 2).   
Generalizability 
It is important to note that observational data should only be used to inform clinical 
trials involving similar cohorts and observational periods. The current study focussed on 
stage 1 HD, the very early clinical phase of the disease, since disease-modifying 
treatments are most likely to be efficacious in preserving function and quality of life 
when administered at this point. Therapies shown to be effective in these cohorts 
within an acceptable safety profile, may be administered during the premanifest stages 
of the disease, prior to clinical onset. The observational PREDICT-HD study, which 
focuses on the premanifest stages of the disease, is ideally positioned to inform the 
design of such trials (Paulsen). 
Limitations 
We must acknowledge the potential limitations of using neuroimaging biomarkers as 
efficacy readouts. It is possible that a positive macrostructural neuroimaging readout 
over six or nine months may not be indicative of longer-term clinical or functional 
improvement.  Although associations between change in neuroimaging measures and 
functional decline have been reported in HD, causality is yet to be demonstrated.6 
Furthermore, these readouts may not be suitable for all types of intervention; their 
utility may be dependent on the mechanism-of-action of the therapy, together with the 
time required for it to mediate an effect.  Nevertheless, these neuroimaging measures 
are show, on average, greater changes in HD cases than controls even over short 
timeframes, reproducible across sites and objective.  They may provide valuable 
biomarkers in the assessment of disease-modifying compounds. 
None of the participants in the current study were enrolled in clinical trials; however, 
many were on medications which target the central nervous system (CNS) 
(Supplemental Table 2). However, mean dosages of CNS-targeting drugs were relatively 
low, with overlap in usage between groups. This study was not designed to examine the 
specific effects of medication on each outcome; however, we acknowledge medication 
usage as a potential confounder.  
 
Conclusion 
The short-interval observational data presented here are complimentary to findings 
over longer intervals in others such as the TRACK-HD and the PREDICT-HD studies.  
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Taken together, these studies can provide data to directly inform the design of clinical 
trials in HD, facilitating the evaluation of treatments designed to slow the course of this 
devastating disease.  Since HD is often regarded as a model neurodegenerative disease, 
amenable to early intervention,1 research into this disorder may inform early-
intervention strategies for more prevalent neurodegenerative diseases.   
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